[New, modern, centrally active antihypertensive agents in the treatment of essential hypertension].
It was recently found that the rise of blood pressure leads to the excitation of a vasomotor centre in the brain stem and that the accompanying decrease in brain cortex excitability results in the reduced sensitivity to various adverse stimuli. Centrally acting antihypertensives, moxonidine and rilmenidine, do not impair circulatory reflexes and therefore do not deprive the patient of a chance to resist the pressure; thus the compliance of the patient might be increased. Both drugs activate I1-imidazoline receptors on the neurons of the rostral ventrolateral medulla oblongata. The reduction of neuronal firing rate results in the decrease of sympathetic activity and arterial pressure. Beside other advantages, centrally acting antihypertensives might be more promising than peripherally acting drugs due to their possible more favourable psychopharmacological profile; this component of their action might be underestimated at present.
Sevcík
J
J
Farmakologický ústav AV, CR.
Masek
K
K
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000627:therapeutic use*; D008526:Medulla Oblongata / Q000187:drug effects / Q000503:physiopathology; D010080:Oxazoles / Q000627:therapeutic use*; D000077769:Rilmenidine
D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D007093:Imidazoles; D010080:Oxazoles; C043482:moxonidine; D000077769:Rilmenidine